In cell culture studies, overexpression of the E2F1 transcription factor has been shown to stimulate proliferation, induce apoptosis, and cooperate with an activated ras gene to oncogenically transform primary rodent cells. To study the eect of increased E2F1 activity on epithelial growth and tumorigenesis in vivo, transgenic mice expressing E2F1 under the control of a keratin 5 (K5) promoter were generated. Expression of E2F1 in the epidermis results in hyperplasia but does not inhibit terminal dierentiation. In a transgenic line expressing high levels of E2F1, mice have decreased hair growth likely as a result of aberrant apoptosis in developing hair follicles. Coexpression of a cyclin D1 transgene with E2F1 augments epidermal hyperplasia and further disrupts hair follicle development suggesting that hypophosphorylated Rb antagonizes the proliferative and apoptotic-promoting activities of E2F1. Finally, the E2F1 transgene is found to cooperate with a v-Ha-ras transgene to induce skin tumors in double transgenic animals. These ®ndings con®rm that many of the activities ascribed to E2F1 through in vitro studies can be reproduced in vivo and demonstrate for the ®rst time that deregulated E2F activity can contribute to tumor development.
Introduction
Functional E2F is made up of a heterodimer consisting of an E2F family member (E2F1, 2, 3, 4, and 5) and a DP protein (DP1 and 2). Several studies have indicated that binding of the Rb tumor suppressor protein, and perhaps other Rb-related proteins, to an E2F/DP heterodimer converts E2F from a transcriptional activator to a transcriptional repressor (Weintraub et al., 1992; Adnane et al., 1995; Bremner et al., 1995; Sellers et al., 1995; Johnson, 1995) . G1 cyclins (D-type cyclins and cyclin E) regulate the interaction between Rb and E2F by activating associated cyclin-dependent kinases (cdks), which in turn phosphorylate and inactivate Rb (Kato et al., 1993; Chellappan et al., 1991) . Cdk inhibitors, such as p16/INK4A and p21/ Cip1, regulate Rb-E2F interaction by inhibiting G1 cyclin kinase activity (reviewed by Hunter and Pines 1994) . These molecules and their interactions are thought to de®ne an important cell cycle checkpoint for the control of cell proliferation (Sherr, 1994; Weinberg, 1995; Hunter and Pines, 1994) . Multiple mitogenic signaling pathways, such as those involving tyrosine kinase receptors, as well as growth inhibitory signals, such as TGF-b, converge at this G1 cyclin-Rb-E2F checkpoint.
As the ®rst member of the E2F gene family to be cloned, E2F1 is the most studied. In quiescent cells such as serum-starved ®broblasts or resting T cells, E2F1 mRNA and E2F1 protein are virtually undetectable (Kaelin et al., 1992; Slansky et al., 1993; Johnson et al., 1994a) . Upon stimulation to enter the cell cycle, E2F1 message and E2F1 protein accumulates at the G1/S phase boundary. This timing of E2F1 induction is consistent with the ®nding that many genes shown to be regulated by E2F are transcriptionally activated in late G1 and early S phase. Transient transfection assays using reporter gene constructs demonstrate that E2F1 can stimulate expression from the promoters of such genes as DHFR, thymidine kinase, DNA polymerase a, cmyb, RB1, HsOrc1, cyclin E and the E2F1 gene itself (Johnson et al., 1993 (Johnson et al., , 1994a Sala et al., 1994; Ohtani et al., 1996; Geng et al., 1996; Ohtani et al., 1995) . Positive regulation by E2F1 of other genes including ribonucleotide reductase, thymidylate synthase, PCNA, cyclin A, cdc2, B-myb, and DP-1 is also suggested by infection of serum-starved rat embryo ®broblast cells by a recombinant adenovirus (De Gregori et al., 1995b) .
In cell culture studies, E2F1 has been shown to have several growth-regulatory properties. Deregulated expression of E2F1 can block serum-starved cells from entering quiescence and induce already quiescent cells to enter S phase (Johnson et al., 1993) . E2F1 expression can also bypass a G1 phase growth arrest induced by Rb, p16/INK4A, TGF-b, and gamma irradiation (Zhu et al., 1993; Lukas et al., 1996; Schwarz et al., 1995; DeGregori et al., 1995a) . Ectopic E2F1 expression has also been found to inhibit terminal dierentiation in both in vitro and in vivo model systems Guy et al., 1996) . In addition, several groups have demonstrated that under some circumstances E2F1 can induce a variety of cell types to undergo programmed cell death or apoptosis in a p53-dependent manner (Wu and Levine, 1994; Qin et al., 1994; Hiebert et al., 1995; Kowalik et al., 1995) .
It has also been demonstrated in a variety of in vitro transformation assays that the E2F1 gene has oncogenic potential. Deregulated expression of E2F1 in cooperation with an activated ras gene can lead to oncogenic transformation of primary rat embryo ®broblasts (Johnson et al., 1994b) . Cells transformed by E2F1 and ras form foci in culture, grow in soft agar, and produce tumors in nude mice. Removal of sequences involved in regulation by Rb or inclusion of the heterodimerization partner DP1 increased the oncogenic potential of E2F1. In immortalized rodent cell lines, E2F1 on its own has been shown to induce anchorage-independent growth (Singh et al., 1994; Xu et al., 1995) . Thus, E2F1 would appear to conform to the widely accepted operational de®nition of an oncogene.
Recently, the simple model that E2F1 functions as a positive regulator of cell proliferation was challenged when two groups reported the generation of mice homozygous for a nonfunctional E2F1 allele (Field et al., 1996; Yamasaki et al., 1996) . Mice lacking E2F1 develop normally, are viable, and show little evidence of hypoproliferative defects. Instead, E2F1 knockout mice demonstrate hyperplasia of some tissues, and older mice develop a variety of aggressive tumors. Thus, in the context of a mouse, E2F1 functions as a tumor suppressor. Based on this ®nding, it might be argued that the oncogenic eect of E2F1 described above is merely an in vitro artifact of cell culture systems. Or it may be that E2F1 is truly unique in that it functions as both an oncogene and a tumor suppressor gene. To examine the eect of deregulated E2F1 expression in vivo, we generated transgenic mice expressing the human E2F1 gene under the control of the bovine keratin 5 (K5) promoter. We ®nd that E2F1 overexpression induces hyperproliferation and contributes to skin tumor development in conjunction with an activated ras oncogene.
Results

Generation of transgenic mice expressing E2F1 under the control of a keratin 5 promoter
The K5 E2F1 transgene was made by subcloning the human E2F1 cDNA into a vector containing a 5.2 kb fragment of the bovine K5 promoter, the rabbit bglobin intron 2, and the SV40 polyadenylation signal (Figure 1a ). This K5 promoter fragment has previously been shown to direct transgene expression to the basal cell compartment of strati®ed squamous epithelia (RamõÂ rez et al., 1994) . Two founder transgenic mice were identi®ed by PCR analysis of tail DNA using primers speci®c for the b-globin intron. Immunohistochemistry on tail sections revealed that one of these transgene-positive mice overexpressed E2F1 in cells of the epidermis. This male founder was used to establish line 1.1. The second transgene-positive mouse, a female, did not show E2F1 overexpression in tail tissue by immunohistochemistry. However, one pup derived from this female was found to harbor the transgene and to overexpress E2F1 in basal keratinocytes. This male ospring was used to derive line 1.0.
The E2F1 transgene is expressed at high levels in primary keratinocytes derived from newborn mice from both lines (Figure 1b) . Expression of the transgene in line 1.0 keratinocytes is approximately 3 ± 4-fold higher than in line 1.1, which correlates with E2F1 protein levels (Figure 1c) . By Western blot analysis using an antibody that detects both mouse found to be increased by 80 and 47-fold, respectively, over that found in nontransgenic keratinocytes. Overexpression of E2F1 was also detected in targeted epithelial tissues by immunohistochemistry. In the skin of K5 E2F1 transgenic mice, high levels of E2F1 are found in cells of the basal layer compartment of the epidermis and the outer root sheath of the hair follicles ( Figure 2a ). E2F1 is also overexpressed in the epithelial lining of the esophagus and bladder and in the epithelial compartment of the thymus (Figure 2b , data not shown). In addition, transgene expression was detected in epithelial tissues of the prostrate, vagina, mammary glands, and salivary glands (data not shown). This pattern of expression matches precisely the expression pattern for the endogenous keratin 5 gene (RamõÂ rez et al., 1994) .
Gross phenotype of K5 E2F1 transgenics
Many line 1.0 mice fail to thrive after birth, resulting in decreased body weight and in some cases death. Line 1.0 mice also have decreased hair growth, which is most pronounced on the top of the head and down the middle of the back. A thickening of facial skin, particularly around the eyes, is also evident in line 1.0 mice. In a nonalbino background (C57 or C3H), line 1.0 mice demonstrate hyperpigmentation of the skin and abnormal pigmentation in the feet and other areas not pigmented in wild-type siblings. At birth, no gross phenotype is observed in line 1.1 mice. However, as line 1.1 mice mature, hyperpigmentation and facial skin thickening become apparent. Moreover, at least some line 1.1 mice begin to lose their hair as they age. Thus, many of the same gross characteristics are found in both K5 E2F1 lines, but the phenotype of line 1.1 mice is less severe.
Hyperplasia and apoptosis in K5 E2F1 transgenic mice
In skin from wild-type mice, the epidermis is one to two cell layers thick and hair follicles are regularly distributed in the skin (Figure 3a ). In younger line 1.1 mice, the majority of the epidermis appears normal with a single layer of keratinocytes. In some areas, however, the epidermis is thickened with increased cellularity ( Figure 3b ). As line 1.1 mice age, the number of these focal areas of hyperplasia increase and become more widespread ( Figure 3c ). The average thickness of the epidermis in older line 1.1 mice is 19.6 mm compared to 10.5 mm in wild-type siblings Figure 4a ). The number of nuclei in line 1.1 epidermis is also increased (Figure 4b ). Line 1.0 skin samples from both young and old mice exhibit obvious epidermal hyperplasia (Figure 3d ). The epidermis of line 1.0 mice is twice as thick as wild-type sibling epidermis and this correlates with an increase in the number of nuclei (Figure 4a,b) . A reduced number of hair follicles and aberrant hair follicle structures are also observed in line 1.0 mice consistent with their sparse coat phenotype (Figure 3d ).
Hyperproliferation in line 1.0 epidermis was con®rmed by determining the per cent of cells in S phase by BrdU incorporation (Figure 4c ). In normal siblings, 3% of interfollicular basal keratinocytes are in S phase. In sharp contrast, 20% of interfollicular basal keratinocytes are in S phase in line 1.0 transgenic mice. At least one other tissue in which E2F1 is overexpressed, the esophagus, also shows an increase in proliferation in line 1.0 transgenic mice compared with normal littermates (Figure 4c ). Line 1.1 transgenic mice did not demonstrate a signi®cant increase in basal epidermal cell proliferation as measured by BrdU incorporation. However, line 1.1 transgenic mice did show an enhanced response to 12-0-tetradecanoylphorbol-13-acetate (TPA) when skin was treated over a 2 week period (Figure 4d) .
In addition to promoting proliferation, E2F1 has also been shown to block dierentiation in several model systems Guy et al., 1996) . Despite the increased thickness and cellularity of the epidermis, the terminal dierentiation program is maintained in K5 E2F1 transgenic mice as evidenced by the presence of apparently normal spinous, granular, and corneal layers (Figure 3 ). Differentiation in line 1.0 transgenic skin was also examined by immunohistochemical staining for the presence of keratin 1 (K1). K1, which is expressed only in cells committed to terminal dierentiation, was found to be abundantly expressed in the suprabasal layer of line 1.0 epidermis (Figure 5c ). Keratin 6 (K6) expression was also examined in the skin of line 1.0 mice. K6 expression is usually restricted to the hair follicles but can be turned on in interfollicular keratinocytes by tumor promoters such as TPA that induce hyperproliferation. Abnormal K6 expression was seen in scattered patches of interfollicular epidermal cells of line 1.0 mice (Figure 5d ) again indicating hyperproliferation. Taken together, these ®ndings demonstrate that forced expression of E2F1 in the epidermis induces proliferation but does not block terminal dierentiation. The TUNEL assay system was employed to determine if E2F1-mediated apoptosis might be responsible for the defect in hair growth seen in line 1.0 mice. In skin samples from older transgenic mice, no obvious increase in apoptosis over background was observed. However, when skin of young mice (2 ± 6 days old) was examined, many condensed, brightly stained nuclei were detected in the developing hair follicles of line 1.0 mice but not in the follicles of wild-type siblings (Figure 6 ). This ®nding of follicular cells undergoing apoptosis may explain the hair growth defect seen in line 1.0 mice.
Cyclin D1 augments the activity of E2F1 in double transgenic mice
A number of studies demonstrate that cyclin D1 is a positive regulator of E2F through its ability to phosphorylate and inactivate Rb (Johnson, 1995; Johnson et al., 1994a; Schulze et al., 1994; Shao and Figure 5 Keratin 1 and 6 expression in line 1.0 transgenic skin. Dorsal skin samples from an untreated K5 E2F1 line 1.0 mice and a wild-type sibling were immunohistochemically analysed with antibody to keratin 1 (K1) or keratin 6 (K6). Shown are wild-type mouse skin staining for K1 (a) and K6 (b) and transgenic skin stained for K1 (c) and K6 (d) Figure 6 Apoptosis in line 1.0 transgenic hair follicles. A TUNEL assay was performed on skin sections from a 6-day old K5 E2F1 line 1.0 transgenic mouse using¯uorescein-dUTP. Several condensed, brightly stained nuclei can be seen in developing hair follicles . To examine the potential synergistic eects of coexpressing cyclin D1 with E2F1, we crossed K5 E2F1 (line 1.0) mice with previously generated K5 cyclin D1 mice (Robles et al., 1996) . The genetic background of both transgenic lines was approximately 90% SSIn. K5 cyclin D1 mice have been shown to have a mild to moderate epithelial hyperplasia but no obvious decrease in hair growth (Robles et al., 1996) . K5 E2F1/cyclin D1 double transgenic mice have a much more severe phenotype than either single transgenic model (Figure 7) . Double transgenic mice have low viability, and those that survive have almost a complete lack of hair. Moreover, the epidermis of double transgenic mice shows a dramatic thickening and increased cellularity compared with the skin of wild-type or single transgenic mice (Figures 7 and 8) . As with the K5 E2F1 line 1.0 transgenic mice, many abnormal hair follicle structures are seen in the skin of double transgenic mice. Thus, coexpression of cyclin D1 with E2F1 augments epidermal hyperproliferation and aberrant hair-follicle development, suggesting that hypophosphorylated Rb antagonizes the induction of these phenotypic characteristics by E2F1.
E2F1 cooperates with v-Ha-ras in tumorigenesis
A transgenic mouse line, termed TG.AC, harboring a v-Ha-ras transgene under the control of a z globin promoter has been described (Leder et al., 1990) . When treated repeatedly with the tumor promoter TPA, these mice develop multiple skin papillomas within 6 weeks. Untreated TG.AC mice occasionally develop spontaneous papillomas late in life (after 8 months) at sites of wounding and chronic abrasion. Thus, these transgenic mice serve as a`preinitiated' model for mouse skin carcinogenesis. We previously demonstrated that E2F1 could cooperate with an activated ras to oncogenically transform primary rat embryo ®broblasts in culture (Johnson et al., 1994b) . To determine if E2F1 could cooperate with activated ras in vivo, K5 E2F1 transgenic mice were crossed with TG.AC transgenic mice.
Many K5 E2F1/TG.AC double transgenic mice develop spontaneous skin papillomas as early as 6 weeks of age (Table 1) . These papillomas are exophytic, well-dierentiated lesions that appear identical to those produced by DMBA/TPA twostage carcinogenesis protocols (Aldaz and Conti, 1989) . Papillomas arise at apparently random sites including on the¯anks, legs, ears and face. Of the 12 double transgenic animals, four of eight males and three of four females have developed papillomas by 24 weeks of age. Thus females are aected as much, if not more, than males suggesting that wounding from ®ghting is not involved in tumor development. As few as one and as many as ®ve tumors have been observed on aected animals for a total of 25 papillomas. No wild-type or single transgenic sibling has developed a papilloma.
Discussion
In the majority of human cancers, the G1 cyclin-Rb-E2F checkpoint is subverted by alteration of one or more of its components. For example, inactivation of either RB1 or p16/INK4A by gene mutation, deletion, or hypermethylation occurs in many dierent tumor types (Weinberg, 1995; Hunter and Pines, 1994) . Rearrangement and overexpression of cyclin D1 (also known as the PRAD1/Bcl1 oncogene) also contributes to the development of several tumors (Sherr, 1994; Hunter and Pines, 1994) . In addition, deregulated expression of other G1 cyclins (D2, D3, and E) has been reported to be associated with tumorigenesis (Sherr, 1994; Hunter and Pines, 1994) . The E7 oncoprotein of human papilloma viruses also targets Rb-E2F complexes by directly binding Rb and releasing free, transcriptionally active E2F (Chellappan et al., 1992) . Although it is assumed that loss of Rb's E2F regulatory function as a consequence of these genetic or epigenetic events contributes to the development of cancer, this has never been directly demonstrated.
A primary reason for generating K5 E2F1 transgenic mice was to directly test whether increased E2F1 activity could contribute to tumorigenesis as is suggested by in vitro transformation assays. The K5 promoter was chosen in part because K5 is expressed in the cell types targeted by human papilloma viruses. In addition, recent studies by Conti and coworkers suggest that activation of the G1 cyclin-Rb-E2F pathway contributes to tumor development during mouse skin multistage carcinogenesis (Bianchi et al., 1993; Robles and Conti, 1995) . Cyclin D1 is constitutively overexpressed in 100% of mouse skin papillomas and squamous cell carcinomas obtained by DMBA/TPA treatment protocols. Moreover, E2F1 protein levels have been shown to be elevated in mouse skin papillomas and squamous cell carcinomas (Zhang et al., 1997) . Thus, overexpression of E2F1 in our transgenic lines mimics in some ways what is seen during mouse skin carcinogenesis.
The ®nding that the K5 E2F1 transgene cooperates with v-Ha-ras to induce papillomas provides the ®rst direct link between upregulation of an E2F protein and tumorigenesis. It has recently been shown that oncogenic ras causes premature replicative senescence accompanied by the accumulation of p53 and p16 (Serrano et al., 1997) . Inactivation of either p53 or p16 or expression of E1A prevents ras-induced senescence and leads to oncogenic transformation. Given that E2F1 is a downstream eector of p16 and E1A activity, it is likely that overexpression of E2F1 may lead to an eect similar to p16 inactivation or E1A expression in response to activated ras.
In addition to ras cooperativity in oncogenic transformation, several other growth regulatory properties of E2F1 demonstrated in cell culture studies are reproduced in this transgenic model. The ability of E2F1 to induce proliferation and apoptosis was particularly pronounced in the line expressing higher levels of E2F1 mRNA and protein. In mice bearing an E2F1 transgene with expression targeted to megakaryocytes, E2F1 also induced proliferation and aberrant apoptosis (Guy et al., 1996) . In contrast to transgenic keratinocytes however, transgenic megakaryocytes were blocked in dierentiation. This may be caused by dierences in the way E2F1 overexpression eects the terminal dierentiation program of these two cell types.
In some ways the phenotypes of our K5 E2F1 transgenic mice are similar to the phenotypes described for transgenics expressing viral oncoproteins that inactivate Rb in basal keratinocytes. One such transgenic mouse expresses an E1A mutant protein, NTd1646, from the mouse K5 promoter (Missero et al., 1993) . This E1A mutant binds Rb and related proteins but not p300 and has reduced transformation activity. Like our line 1.0 mice, K5 NTd1646 transgenic mice are smaller and have a lack of hair that is most pronounced on the top of the head and down the middle of the back. Like our line 1.1 mice, little hyperproliferation was observed in interfollicular epidermis of K5 NTd1646 transgenic mice. A set of transgenic mice expressing E7 under the control of a keratin 14 (K14) promoter also shows similarities to K5 E2F1 mice (Herber et al., 1996) . K14 E7 mice demonstrate stunted growth, epidermal hyperplasia and lack of hair like K5 E2F1 mice. K14 E7 mice also developed skin tumors late in life with low penetrance.
Transgenic mice expressing cyclin D1 under the control of the same bovine K5 promoter also show evidence of epidermal hyperproliferation but no overt defect in hair follicle development is observed (Robles et al., 1996) . Given these similarities, it is likely that the phenotypes caused by the E1A mutant, E7, and cyclin D1 are at least in part the result of the release of E2F factors from negative regulation by Rb and Rb-related proteins. Our ®nding that coexpression of cyclin D1 and E2F1 greatly augments epidermal hyperplasia further supports the idea that hypophosphorylated Rb plays an important role in regulating the growth-promoting activity of E2F1. Moreover, if increased apoptosis is responsible for the almost complete lack of hair seen in K5 E2F1/cyclin D1 double transgenic animals, then Rb would also appear to play an important role in inhibiting apoptosis mediated by E2F1.
E2F1-mediated apoptosis has been shown to be largely dependent on wild-type p53 function. Preliminary results with crosses between line 1.0 transgenic mice and p53 knockout mice suggests that the hair growth defect is at least partially dependent on wild-type p53 (data not shown), consistent with our ®nding of apoptosis in developing hair follicles. Moreover, several K5 E2F1 transgenic mice heterozygous for p53 have developed skin tumors suggesting that E2F1 may also cooperate with loss of p53 in tumorigenesis. If this is con®rmed by additional experiments, this would provide further support for E2F1's dual classi®cation as both an oncogene and a tumor suppressor gene.
Materials and methods
Construction of the K5 E2F1 transgene and generation of transgenic mice lines
A bluescript KS(7) plasmid containing a 5.2 kb fragment from the bovine K5 promoter, a 0.6 kb fragment containing the rabbit b-globin intron and a 1.1 kb fragment containing two 3' poly A signal sequences was obtained from Dr David Bohls and John DiGiovanni (The University of Texas, MD Anderson Cancer Center, Smithville, Texas, USA). This plasmid was derived from constructs originally obtained from Dr Jose Jorcano (CIEMAT, Madrid, Spain). A 1.4 kb fragment containing the full-length human E2F1 cDNA was cut from CMV E2F1 (Johnson et al. 1993) using HindIII (followed by klenow) and XbaI and inserted into the K5 vector using SnaBI (blunt) and NheI (compatible with XbaI). The transgene was isolated by cutting with Acc65I followed by agarose gel electrophoresis and Qiaex (Qiagen) puri®cation.
Founder transgenic mice were made by microinjecting the transgene into C57BL/6J6SJL/J F2 hybrid zygotes. Lines were established and maintained by breeding founders to the SENCAR inbred strain SSIN followed by backcrossing to SSIN. All lines were approximately 90% SSIN genetically for the double transgenic crossing experiments between K5 E2F1 and K5 cyclin D1 or TG.AC. K5 E2F1 founders were also crossed with C3H and C57 mice for some experiments. In these cases, transgenic mice were always directly compared to nontransgenic siblings.
Western and Northern blot analysis of primary transgenic keratinocytes
Primary keratinocytes were isolated from newborn mice by incubating washed skins in 0.25% trypsin/phosphatebuered saline (PBS) overnight at 48C. Epidermis was then separated from the dermis, minced in culture media, and stirred for 20 min. The cell suspension was ®ltered through nylon mesh, cells counted, and plated at a density of 3 million/35 mm dish. Media was changed after 2 h and harvested after 48 h.
Whole cell protein extract was prepared by resuspending washed cells in lysis buer (50 mM HEPES, pH 7.9, 250 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% NP40, 0.4 mM NaF, 0.4 mM Na 3 VO 4 , 10% glycerol, 1 mM DTT, 0.5 mM PMSF, 2 mg/ml aprotinin, 2 mg/ml leupeptin, and 1 mg/ml pepstatin), freeze thawing, and collecting supernatant following high-speed centrifugation. SDS ± PAGE was performed on protein samples (10 ± 15 mg) using a 7.5% gel, and transferred to nitrocellulose membrane. E2F1 antibody was purchased from Santa Cruz Biotechnology.
For Northern blot analysis, total RNA was isolated using Tri reagent (Molecular Research Center, Inc.) and manufacturer's protocol. Twenty mg of RNA was run on a 1% formaldehyde-agarose gel at 5 v/cm for 3.5 h. A random primed-labeled 1.4 kb fragment of the human E2F1 cDNA was used as the probe.
E2F1 immunohistostaining
Formalin-®xed tissue sections were deparanized and ®xed in methanol containing 1% hydrogen peroxide for 20 min. Tissue sections were then rinsed with PBS containing 0.1% BSA three times for 5 min each. Slides were boiled for 5 min and again rinsed in PBS/BSA. Sections were preincubated with normal goat serum for 20 min before addition of primary E2F1 antibody (1 : 500, Santa Cruz Biotechnology). Sections were incubated for 30 min, rinsed with PBS/BSA, and then incubated with biotinylated antirabbit IgG for 30 min. Slides were rinsed with PBS/BSA and developed with streptaviden-horseradish peroxidase conjugate and diaminobenzidine (DAB) substrate. Tissue sections were rinsed again and counterstained before mounting.
BrdU incorporation
Mice were injected intraperitoneally with 0.06 mg BrdU per gram of body weight, allowed to incorporate for 30 min, and sacri®ced. In the case where TPA was applied, BrdU was injected 24 h following the ®nal TPA application. Skin samples were collected, ®xed in formalin, and paranembedded. Tissue sections were then subjected to immunohistochemistry as described above using antibody (Becton Dickinson) speci®c for BrdU. For determining per cent incorporation, interfollicular basal cells were examined, and the number of unstained and stained cells was determined. At least 300 cells were counted in two independent tissue sections before averaging results.
TUNEL assay
Skin tissue from transgenic mice and wild-type siblings was ®xed in formalin, paran embedded, and sectioned. Following deparanization and hydration, sections were incubated in the TUNEL reaction mixture containing TdT and¯ourescein-dUTP per manufacture's instructions (Boehringer Mannheim, in situ cell death detection kit). Sections were washed, and the label incorporated in apoptotic cells was visualized by¯uorescence microscopy.
